Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280172 | 1.00 | LMNA (0.42) | LMNASMN1; SMN2TYMSDNMT1ADRB1 | |
| SCHEMBL2587213 | 0.88 | LMNA (0.37) | LMNASMN1; SMN2POLB | |
| SCHEMBL2588008 | 0.85 | LMNA (0.58) | LMNASMN1; SMN2DNMT1ADRB1 | |
| SCHEMBL4276793 | 0.85 | LMNA (0.58) | LMNASMN1; SMN2DNMT1ADRB1 | |
| SCHEMBL9084630 | 0.82 | BCHE (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL2587513 | 0.78 | RNASE1 (0.40) | LMNASMN1; SMN2POLB | |
| SCHEMBL4277164 | 0.78 | LMNA (0.70) | LMNASMN1; SMN2TYMS | |
| SCHEMBL4277166 | 0.78 | LMNA (0.70) | LMNASMN1; SMN2TYMS | |
| SCHEMBL25492056 | 0.78 | LMNA (0.57) | LMNASMN1; SMN2DNMT1ADRB1 | |
| SCHEMBL2578394 | 0.77 | LMNA (0.40) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | LMNA 256/4885SMN1; SMN2 2604/4885TYMS 19/4885 |
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | SAMHD1, TYMP, NUDT1 | LMNA 560/4885SMN1; SMN2 1392/4885TYMS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.